Lantheus (NASDAQ:LNTH) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Lantheus (NASDAQ:LNTH) from a hold rating to a sell rating in a research report sent to investors on Friday morning, Zacks.com reports.

According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “

A number of other equities research analysts have also commented on LNTH. ValuEngine lowered shares of Lantheus from a buy rating to a hold rating in a research note on Thursday. BidaskClub lowered shares of Lantheus from a strong-buy rating to a buy rating in a research note on Tuesday, June 11th.

LNTH remained flat at $$22.49 during trading on Friday. 428,304 shares of the company’s stock were exchanged, compared to its average volume of 438,680. Lantheus has a 52-week low of $12.59 and a 52-week high of $29.80. The company has a quick ratio of 2.01, a current ratio of 2.62 and a debt-to-equity ratio of 2.05. The stock has a market cap of $873.06 million, a PE ratio of 23.93, a PEG ratio of 1.79 and a beta of 1.48. The business’s 50 day simple moving average is $26.98.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported $0.27 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.27. Lantheus had a net margin of 11.20% and a return on equity of 51.08%. The company had revenue of $85.70 million for the quarter, compared to analyst estimates of $88.72 million. During the same period in the prior year, the firm posted $0.25 EPS. The company’s quarterly revenue was up .1% on a year-over-year basis. On average, sell-side analysts expect that Lantheus will post 1.06 EPS for the current year.

In other news, SVP Michael P. Duffy sold 8,819 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $28.14, for a total value of $248,166.66. Following the sale, the senior vice president now directly owns 144,494 shares of the company’s stock, valued at approximately $4,066,061.16. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Cesare Orlandi sold 35,586 shares of the company’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $28.17, for a total transaction of $1,002,457.62. Following the completion of the sale, the insider now directly owns 75,155 shares in the company, valued at $2,117,116.35. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 146,187 shares of company stock worth $3,853,913. Insiders own 2.60% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its stake in Lantheus by 2.0% during the fourth quarter. Bank of New York Mellon Corp now owns 451,564 shares of the medical equipment provider’s stock worth $7,067,000 after acquiring an additional 9,033 shares in the last quarter. Advisor Group Inc. boosted its stake in Lantheus by 1,837.2% during the fourth quarter. Advisor Group Inc. now owns 4,378 shares of the medical equipment provider’s stock worth $69,000 after acquiring an additional 4,152 shares in the last quarter. Northern Trust Corp boosted its stake in Lantheus by 0.6% during the fourth quarter. Northern Trust Corp now owns 475,961 shares of the medical equipment provider’s stock worth $7,448,000 after acquiring an additional 2,723 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Lantheus by 5.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,379,017 shares of the medical equipment provider’s stock worth $21,581,000 after acquiring an additional 65,609 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Lantheus by 15.3% during the fourth quarter. Geode Capital Management LLC now owns 428,939 shares of the medical equipment provider’s stock worth $6,712,000 after acquiring an additional 56,935 shares in the last quarter. 91.50% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Read More: What is the Quick Ratio?

Get a free copy of the Zacks research report on Lantheus (LNTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.